{
    "articles": {
        "id": 0,
        "pmid": "35964471",
        "title": "Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria",
        "author": "Larkin J",
        "journal": "Eur J Cancer",
        "year": 2022,
        "article": "[\"PURPOSE: Nivolumab was approved as adjuvant therapy for melanoma based on data from CheckMate 238, which enrolled patients per American Joint Committee on Cancer version 7 (AJCC-7) criteria.\", \"Here, we analyse long-term outcomes per AJCC-8 staging criteria compared with AJCC-7 results to inform clinical decisions for patients diagnosed per AJCC-8.\", \"PATIENTS AND METHODS: In a double-blind, phase 3 trial (NCT02388906), patients aged ≥15 years with resected, histologically confirmed AJCC-7 stage IIIB, IIIC, or IV melanoma were randomised to receive nivolumab 3 mg/kg every 2 weeks or ipilimumab 10 mg/kg every 3 weeks for 4 doses and then every 12 weeks, both intravenously ≤1 year.\", \"Recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) were assessed in patients with stage III disease, per AJCC-7 and AJCC-8.\", \"RESULTS: Per AJCC-7 staging, 42.4% and 57.3% of patients were in substage IIIB and IIIC, respectively; per AJCC-8, 1.1%, 30.4%, 62.8%, and 5.0% were in IIIA, IIIB, IIIC, and IIID.\", \"After 4 years' minimum follow-up, the AJCC-7 superior efficacy of nivolumab over ipilimumab in patients with resected stage III melanoma was preserved per AJCC-8 analysis.\", \"No statistically significant difference in RFS between stage III substage hazard ratios was observed per AJCC-7 or -8 staging criteria (interaction test: AJCC-7, P = 0.8115; AJCC-8, P = 0.1051; P = 0.8392 ((AJCC-7) and P = 0.8678 (AJCC-8) for DMFS).\", \"CONCLUSIONS: CheckMate 238 4-year RFS and DMFS outcomes are consistent per AJCC-7 and AJCC-8 staging criteria.\", \"Outcome benefits can therefore be translated for patients diagnosed per AJCC-8.\"]",
        "article_tokens": "[[\"PURPOSE\", \":\", \"Nivolumab\", \"was\", \"approved\", \"as\", \"adjuvant\", \"therapy\", \"for\", \"melanoma\", \"based\", \"on\", \"data\", \"from\", \"CheckMate\", \"238\", \",\", \"which\", \"enrolled\", \"patients\", \"per\", \"American\", \"Joint\", \"Committee\", \"on\", \"Cancer\", \"version\", \"7\", \"(\", \"AJCC-7\", \")\", \"criteria\", \".\"], [\"Here\", \",\", \"we\", \"analyse\", \"long-term\", \"outcomes\", \"per\", \"AJCC-8\", \"staging\", \"criteria\", \"compared\", \"with\", \"AJCC-7\", \"results\", \"to\", \"inform\", \"clinical\", \"decisions\", \"for\", \"patients\", \"diagnosed\", \"per\", \"AJCC-8\", \".\"], [\"PATIENTS\", \"AND\", \"METHODS\", \":\", \"In\", \"a\", \"double-blind\", \",\", \"phase\", \"3\", \"trial\", \"(\", \"NCT02388906\", \")\", \",\", \"patients\", \"aged\", \"≥15\", \"years\", \"with\", \"resected\", \",\", \"histologically\", \"confirmed\", \"AJCC-7\", \"stage\", \"IIIB\", \",\", \"IIIC\", \",\", \"or\", \"IV\", \"melanoma\", \"were\", \"randomised\", \"to\", \"receive\", \"nivolumab\", \"3\", \"mg/kg\", \"every\", \"2\", \"weeks\", \"or\", \"ipilimumab\", \"10\", \"mg/kg\", \"every\", \"3\", \"weeks\", \"for\", \"4\", \"doses\", \"and\", \"then\", \"every\", \"12\", \"weeks\", \",\", \"both\", \"intravenously\", \"≤1\", \"year\", \".\"], [\"Recurrence-free\", \"survival\", \"(\", \"RFS\", \")\", \"and\", \"distant\", \"metastasis-free\", \"survival\", \"(\", \"DMFS\", \")\", \"were\", \"assessed\", \"in\", \"patients\", \"with\", \"stage\", \"III\", \"disease\", \",\", \"per\", \"AJCC-7\", \"and\", \"AJCC-8\", \".\"], [\"RESULTS\", \":\", \"Per\", \"AJCC-7\", \"staging\", \",\", \"42.4\", \"%\", \"and\", \"57.3\", \"%\", \"of\", \"patients\", \"were\", \"in\", \"substage\", \"IIIB\", \"and\", \"IIIC\", \",\", \"respectively\", \";\", \"per\", \"AJCC-8\", \",\", \"1.1\", \"%\", \",\", \"30.4\", \"%\", \",\", \"62.8\", \"%\", \",\", \"and\", \"5.0\", \"%\", \"were\", \"in\", \"IIIA\", \",\", \"IIIB\", \",\", \"IIIC\", \",\", \"and\", \"IIID\", \".\"], [\"After\", \"4\", \"years\", \"'\", \"minimum\", \"follow-up\", \",\", \"the\", \"AJCC-7\", \"superior\", \"efficacy\", \"of\", \"nivolumab\", \"over\", \"ipilimumab\", \"in\", \"patients\", \"with\", \"resected\", \"stage\", \"III\", \"melanoma\", \"was\", \"preserved\", \"per\", \"AJCC-8\", \"analysis\", \".\"], [\"No\", \"statistically\", \"significant\", \"difference\", \"in\", \"RFS\", \"between\", \"stage\", \"III\", \"substage\", \"hazard\", \"ratios\", \"was\", \"observed\", \"per\", \"AJCC-7\", \"or\", \"-8\", \"staging\", \"criteria\", \"(\", \"interaction\", \"test\", \":\", \"AJCC-7\", \",\", \"P\", \"=\", \"0.8115\", \";\", \"AJCC-8\", \",\", \"P\", \"=\", \"0.1051\", \";\", \"P\", \"=\", \"0.8392\", \"(\", \"(\", \"AJCC-7\", \")\", \"and\", \"P\", \"=\", \"0.8678\", \"(\", \"AJCC-8\", \")\", \"for\", \"DMFS\", \")\", \".\"], [\"CONCLUSIONS\", \":\", \"CheckMate\", \"238\", \"4-year\", \"RFS\", \"and\", \"DMFS\", \"outcomes\", \"are\", \"consistent\", \"per\", \"AJCC-7\", \"and\", \"AJCC-8\", \"staging\", \"criteria\", \".\"], [\"Outcome\", \"benefits\", \"can\", \"therefore\", \"be\", \"translated\", \"for\", \"patients\", \"diagnosed\", \"per\", \"AJCC-8\", \".\"]]",
        "summaries": "[{\"kes\": [{\"index\": 15, \"sentence\": 1}, {\"index\": 16, \"sentence\": 1}, {\"index\": 17, \"sentence\": 1}, {\"index\": 18, \"sentence\": 1}, {\"index\": 19, \"sentence\": 1}, {\"index\": 20, \"sentence\": 1}, {\"index\": 21, \"sentence\": 1}, {\"index\": 22, \"sentence\": 1}, {\"index\": 4, \"sentence\": 1}, {\"index\": 5, \"sentence\": 1}, {\"index\": 6, \"sentence\": 1}, {\"index\": 7, \"sentence\": 1}, {\"index\": 8, \"sentence\": 1}, {\"index\": 9, \"sentence\": 1}, {\"index\": 10, \"sentence\": 1}, {\"index\": 11, \"sentence\": 1}, {\"index\": 12, \"sentence\": 1}, {\"index\": 13, \"sentence\": 1}, {\"index\": 14, \"sentence\": 1}], \"error\": \"\", \"aspect\": \"ob\", \"status\": 1, \"summary\": \"The objective is to report long-term outcomes per AJCC-8 staging criteria compared with AJCC-7 results to inform clinical decisions for patients diagnosed per AJCC-8.\", \"evaluating\": false, \"com_eval_kps\": 5, \"con_eval_kps\": 5, \"com_eval_summary\": 5, \"con_eval_summary\": 5, \"com_eval_sentences\": 5, \"con_eval_sentences\": 5}, {\"kes\": [{\"index\": 2, \"sentence\": 0}, {\"index\": 34, \"sentence\": 2}, {\"index\": 35, \"sentence\": 2}, {\"index\": 36, \"sentence\": 2}, {\"index\": 37, \"sentence\": 2}, {\"index\": 38, \"sentence\": 2}, {\"index\": 39, \"sentence\": 2}, {\"index\": 40, \"sentence\": 2}, {\"index\": 41, \"sentence\": 2}, {\"index\": 42, \"sentence\": 2}, {\"index\": 43, \"sentence\": 2}, {\"index\": 44, \"sentence\": 2}, {\"index\": 45, \"sentence\": 2}, {\"index\": 46, \"sentence\": 2}, {\"index\": 48, \"sentence\": 2}, {\"index\": 47, \"sentence\": 2}, {\"index\": 49, \"sentence\": 2}, {\"index\": 50, \"sentence\": 2}, {\"index\": 51, \"sentence\": 2}, {\"index\": 52, \"sentence\": 2}, {\"index\": 53, \"sentence\": 2}, {\"index\": 54, \"sentence\": 2}, {\"index\": 55, \"sentence\": 2}, {\"index\": 56, \"sentence\": 2}, {\"index\": 57, \"sentence\": 2}, {\"index\": 58, \"sentence\": 2}, {\"index\": 59, \"sentence\": 2}, {\"index\": 60, \"sentence\": 2}, {\"index\": 61, \"sentence\": 2}, {\"index\": 62, \"sentence\": 2}], \"error\": \"\", \"aspect\": \"i\", \"status\": 1, \"summary\": \"Patients were randomly assigned to receive nivolumab 3 mg/kg every 2 weeks or ipilimumab 10 mg/kg every 3 weeks for 4 doses and then every 12 weeks, both intravenously ≤1 year.\", \"evaluating\": false, \"com_eval_kps\": 5, \"con_eval_kps\": 5, \"com_eval_summary\": 5, \"con_eval_summary\": 5, \"com_eval_sentences\": 5, \"con_eval_sentences\": 5}, {\"kes\": [{\"index\": 44, \"sentence\": 2}, {\"index\": 45, \"sentence\": 2}, {\"index\": 46, \"sentence\": 2}, {\"index\": 47, \"sentence\": 2}, {\"index\": 49, \"sentence\": 2}, {\"index\": 48, \"sentence\": 2}, {\"index\": 50, \"sentence\": 2}, {\"index\": 51, \"sentence\": 2}, {\"index\": 52, \"sentence\": 2}, {\"index\": 53, \"sentence\": 2}, {\"index\": 54, \"sentence\": 2}, {\"index\": 55, \"sentence\": 2}, {\"index\": 56, \"sentence\": 2}, {\"index\": 57, \"sentence\": 2}, {\"index\": 60, \"sentence\": 2}, {\"index\": 61, \"sentence\": 2}, {\"index\": 62, \"sentence\": 2}, {\"index\": 14, \"sentence\": 5}], \"error\": \"\", \"aspect\": \"c\", \"status\": 1, \"summary\": \"The comparator was ipilimumab 10 mg/kg every 3 weeks for 4 doses and then every 12 weeks, intravenously ≤1 year.\", \"evaluating\": false, \"com_eval_kps\": 5, \"con_eval_kps\": 5, \"com_eval_summary\": 5, \"con_eval_summary\": 5, \"com_eval_sentences\": 5, \"con_eval_sentences\": 5}, {\"kes\": [{\"index\": 6, \"sentence\": 2}], \"error\": \"\", \"aspect\": \"b\", \"status\": 1, \"summary\": \"The study was double-blind.\", \"evaluating\": false, \"com_eval_kps\": 5, \"con_eval_kps\": 5, \"com_eval_summary\": 5, \"con_eval_summary\": 5, \"com_eval_sentences\": 5, \"con_eval_sentences\": 5}, {\"kes\": [{\"index\": 15, \"sentence\": 2}, {\"index\": 16, \"sentence\": 2}, {\"index\": 17, \"sentence\": 2}, {\"index\": 18, \"sentence\": 2}, {\"index\": 19, \"sentence\": 2}, {\"index\": 21, \"sentence\": 2}, {\"index\": 20, \"sentence\": 2}, {\"index\": 22, \"sentence\": 2}, {\"index\": 23, \"sentence\": 2}, {\"index\": 24, \"sentence\": 2}, {\"index\": 25, \"sentence\": 2}, {\"index\": 26, \"sentence\": 2}, {\"index\": 27, \"sentence\": 2}, {\"index\": 28, \"sentence\": 2}, {\"index\": 29, \"sentence\": 2}, {\"index\": 30, \"sentence\": 2}, {\"index\": 31, \"sentence\": 2}, {\"index\": 32, \"sentence\": 2}], \"error\": \"\", \"aspect\": \"p\", \"status\": 1, \"summary\": \"Patients aged ≥15 years with resected, histologically confirmed AJCC-7 stage IIIB, IIIC, or IV melanoma were included in this study.\", \"evaluating\": false, \"com_eval_kps\": 5, \"con_eval_kps\": 5, \"com_eval_summary\": 5, \"con_eval_summary\": 5, \"com_eval_sentences\": 5, \"con_eval_sentences\": 5}, {\"kes\": [{\"index\": 2, \"sentence\": 0}, {\"index\": 44, \"sentence\": 2}, {\"index\": 37, \"sentence\": 2}, {\"index\": 12, \"sentence\": 5}], \"error\": \"\", \"aspect\": \"m\", \"status\": 1, \"summary\": \"The medicines involved were nivolumab and ipilimumab.\", \"evaluating\": false, \"com_eval_kps\": 5, \"con_eval_kps\": 5, \"com_eval_summary\": 5, \"con_eval_summary\": 5, \"com_eval_sentences\": 5, \"con_eval_sentences\": 5}, {\"kes\": [{\"index\": 40, \"sentence\": 2}, {\"index\": 41, \"sentence\": 2}, {\"index\": 42, \"sentence\": 2}, {\"index\": 50, \"sentence\": 2}, {\"index\": 51, \"sentence\": 2}, {\"index\": 52, \"sentence\": 2}, {\"index\": 53, \"sentence\": 2}, {\"index\": 54, \"sentence\": 2}, {\"index\": 55, \"sentence\": 2}, {\"index\": 56, \"sentence\": 2}, {\"index\": 57, \"sentence\": 2}, {\"index\": 61, \"sentence\": 2}, {\"index\": 62, \"sentence\": 2}], \"error\": \"\", \"aspect\": \"td\", \"status\": 1, \"summary\": \"The treatment duration is was every 2 weeks for 4 doses and then every 12 weeks (less than a year).\", \"evaluating\": false, \"com_eval_kps\": 5, \"con_eval_kps\": 5, \"com_eval_summary\": 5, \"con_eval_summary\": 4, \"com_eval_sentences\": 5, \"con_eval_sentences\": 5}, {\"kes\": [{\"index\": 0, \"sentence\": 3}, {\"index\": 1, \"sentence\": 3}, {\"index\": 2, \"sentence\": 3}, {\"index\": 3, \"sentence\": 3}, {\"index\": 4, \"sentence\": 3}, {\"index\": 5, \"sentence\": 3}, {\"index\": 6, \"sentence\": 3}, {\"index\": 7, \"sentence\": 3}, {\"index\": 8, \"sentence\": 3}, {\"index\": 9, \"sentence\": 3}, {\"index\": 10, \"sentence\": 3}, {\"index\": 11, \"sentence\": 3}, {\"index\": 12, \"sentence\": 3}, {\"index\": 13, \"sentence\": 3}], \"error\": \"\", \"aspect\": \"pe\", \"status\": 1, \"summary\": \"Recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) were primary endpoints.\", \"evaluating\": false, \"com_eval_kps\": 5, \"con_eval_kps\": 5, \"com_eval_summary\": 5, \"con_eval_summary\": 4, \"com_eval_sentences\": 5, \"con_eval_sentences\": 5}, {\"kes\": [{\"index\": 0, \"sentence\": 5}, {\"index\": 1, \"sentence\": 5}, {\"index\": 2, \"sentence\": 5}, {\"index\": 3, \"sentence\": 5}, {\"index\": 4, \"sentence\": 5}, {\"index\": 5, \"sentence\": 5}, {\"index\": 4, \"sentence\": 7}], \"error\": \"\", \"aspect\": \"fd\", \"status\": 1, \"summary\": \"The minumum follow-up duration was 4 years.\", \"evaluating\": false, \"com_eval_kps\": 5, \"con_eval_kps\": 5, \"com_eval_summary\": 5, \"con_eval_summary\": 5, \"com_eval_sentences\": 5, \"con_eval_sentences\": 5}, {\"kes\": [{\"index\": 0, \"sentence\": 3}, {\"index\": 1, \"sentence\": 3}, {\"index\": 3, \"sentence\": 3}, {\"index\": 2, \"sentence\": 3}, {\"index\": 4, \"sentence\": 3}, {\"index\": 5, \"sentence\": 3}, {\"index\": 6, \"sentence\": 3}, {\"index\": 7, \"sentence\": 3}, {\"index\": 8, \"sentence\": 3}, {\"index\": 9, \"sentence\": 3}, {\"index\": 10, \"sentence\": 3}, {\"index\": 11, \"sentence\": 3}, {\"index\": 0, \"sentence\": 6}, {\"index\": 1, \"sentence\": 6}, {\"index\": 2, \"sentence\": 6}, {\"index\": 3, \"sentence\": 6}, {\"index\": 5, \"sentence\": 6}, {\"index\": 4, \"sentence\": 6}, {\"index\": 6, \"sentence\": 6}, {\"index\": 8, \"sentence\": 6}, {\"index\": 7, \"sentence\": 6}, {\"index\": 9, \"sentence\": 6}, {\"index\": 10, \"sentence\": 6}, {\"index\": 11, \"sentence\": 6}, {\"index\": 12, \"sentence\": 6}, {\"index\": 13, \"sentence\": 6}, {\"index\": 14, \"sentence\": 6}, {\"index\": 15, \"sentence\": 6}, {\"index\": 16, \"sentence\": 6}, {\"index\": 18, \"sentence\": 6}, {\"index\": 17, \"sentence\": 6}, {\"index\": 19, \"sentence\": 6}, {\"index\": 5, \"sentence\": 7}, {\"index\": 6, \"sentence\": 7}, {\"index\": 7, \"sentence\": 7}, {\"index\": 8, \"sentence\": 7}, {\"index\": 9, \"sentence\": 7}, {\"index\": 10, \"sentence\": 7}, {\"index\": 12, \"sentence\": 7}, {\"index\": 11, \"sentence\": 7}, {\"index\": 13, \"sentence\": 7}, {\"index\": 14, \"sentence\": 7}, {\"index\": 15, \"sentence\": 7}, {\"index\": 16, \"sentence\": 7}, {\"index\": 20, \"sentence\": 6}, {\"index\": 21, \"sentence\": 6}, {\"index\": 22, \"sentence\": 6}, {\"index\": 24, \"sentence\": 6}, {\"index\": 23, \"sentence\": 6}, {\"index\": 26, \"sentence\": 6}, {\"index\": 25, \"sentence\": 6}, {\"index\": 27, \"sentence\": 6}, {\"index\": 28, \"sentence\": 6}, {\"index\": 29, \"sentence\": 6}, {\"index\": 30, \"sentence\": 6}, {\"index\": 31, \"sentence\": 6}, {\"index\": 32, \"sentence\": 6}, {\"index\": 33, \"sentence\": 6}, {\"index\": 34, \"sentence\": 6}, {\"index\": 35, \"sentence\": 6}, {\"index\": 36, \"sentence\": 6}, {\"index\": 37, \"sentence\": 6}, {\"index\": 38, \"sentence\": 6}, {\"index\": 39, \"sentence\": 6}, {\"index\": 40, \"sentence\": 6}, {\"index\": 41, \"sentence\": 6}, {\"index\": 42, \"sentence\": 6}, {\"index\": 43, \"sentence\": 6}, {\"index\": 44, \"sentence\": 6}, {\"index\": 45, \"sentence\": 6}, {\"index\": 46, \"sentence\": 6}, {\"index\": 47, \"sentence\": 6}, {\"index\": 48, \"sentence\": 6}, {\"index\": 49, \"sentence\": 6}, {\"index\": 50, \"sentence\": 6}, {\"index\": 51, \"sentence\": 6}, {\"index\": 52, \"sentence\": 6}], \"error\": \"\", \"aspect\": \"o\", \"status\": 1, \"summary\": \"No statistically significant difference between Recurrence-free survival (RFS) stage III substage hazard ratios was observed per AJCC-7 or -8 staging criteria (interaction test: AJCC-7, P = 0.8115; AJCC-8, P = 0.1051; P = 0.8392 ((AJCC-7) and P = 0.8678 (AJCC-8) for and distant metastasis-free survival (DMFS)).\", \"evaluating\": false, \"com_eval_kps\": 5, \"con_eval_kps\": 5, \"com_eval_summary\": 5, \"con_eval_summary\": 5, \"com_eval_sentences\": 5, \"con_eval_sentences\": 5}, {\"kes\": [{\"index\": 1, \"sentence\": 8}, {\"index\": 2, \"sentence\": 8}, {\"index\": 4, \"sentence\": 8}, {\"index\": 5, \"sentence\": 8}, {\"index\": 6, \"sentence\": 8}, {\"index\": 7, \"sentence\": 8}, {\"index\": 8, \"sentence\": 8}, {\"index\": 9, \"sentence\": 8}, {\"index\": 10, \"sentence\": 8}, {\"index\": 4, \"sentence\": 7}, {\"index\": 5, \"sentence\": 7}, {\"index\": 7, \"sentence\": 7}, {\"index\": 6, \"sentence\": 7}, {\"index\": 8, \"sentence\": 7}, {\"index\": 9, \"sentence\": 7}, {\"index\": 10, \"sentence\": 7}, {\"index\": 11, \"sentence\": 7}, {\"index\": 12, \"sentence\": 7}, {\"index\": 13, \"sentence\": 7}, {\"index\": 14, \"sentence\": 7}, {\"index\": 15, \"sentence\": 7}, {\"index\": 9, \"sentence\": 5}, {\"index\": 10, \"sentence\": 5}, {\"index\": 11, \"sentence\": 5}, {\"index\": 12, \"sentence\": 5}, {\"index\": 13, \"sentence\": 5}, {\"index\": 14, \"sentence\": 5}, {\"index\": 15, \"sentence\": 5}, {\"index\": 16, \"sentence\": 5}, {\"index\": 17, \"sentence\": 5}, {\"index\": 18, \"sentence\": 5}, {\"index\": 19, \"sentence\": 5}, {\"index\": 20, \"sentence\": 5}, {\"index\": 21, \"sentence\": 5}, {\"index\": 22, \"sentence\": 5}, {\"index\": 23, \"sentence\": 5}, {\"index\": 24, \"sentence\": 5}, {\"index\": 25, \"sentence\": 5}, {\"index\": 26, \"sentence\": 5}], \"error\": \"\", \"aspect\": \"f\", \"status\": 1, \"summary\": \"Superior efficacy of nivolumab over ipilimumab in patients diagnosed per AJCC-7 is consistent with patient diagnosed per AJCC-8 staging criteria .\", \"evaluating\": false, \"com_eval_kps\": 5, \"con_eval_kps\": 5, \"com_eval_summary\": 5, \"con_eval_summary\": 5, \"com_eval_sentences\": 5, \"con_eval_sentences\": 5}, {\"kes\": [{\"index\": 14, \"sentence\": 0}, {\"index\": 15, \"sentence\": 0}], \"error\": \"\", \"aspect\": \"rf\", \"status\": 1, \"summary\": \"CheckMate 238\", \"evaluating\": false, \"com_eval_kps\": 5, \"con_eval_kps\": 5, \"com_eval_summary\": 5, \"con_eval_summary\": 5, \"com_eval_sentences\": 5, \"con_eval_sentences\": 5}]",
        "status": 1,
        "annotator": "",
        "updated_at": ""
    },
    "status": 0
}